{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:20:02Z","timestamp":1793737202603,"version":"4.6.1"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["CZ.02.01.01\/00\/22_008\/0004644"],"award-info":[{"award-number":["CZ.02.01.01\/00\/22_008\/0004644"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002969","name":"Technologick\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["TQ03000338"],"award-info":[{"award-number":["TQ03000338"]}],"id":[{"id":"10.13039\/501100002969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002969","name":"Technologick\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["LM2023067"],"award-info":[{"award-number":["LM2023067"]}],"id":[{"id":"10.13039\/501100002969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013855","name":"Ministerstvo \u017divotn\u00edho Prost\u0159ed\u00ed","doi-asserted-by":"publisher","award":["No. CZ.10.03.01\/00\/22_003\/0000003"],"award-info":[{"award-number":["No. CZ.10.03.01\/00\/22_003\/0000003"]}],"id":[{"id":"10.13039\/501100013855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU23\u201003\u201000374"],"award-info":[{"award-number":["NU23\u201003\u201000374"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006704","name":"University of Ostrava","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006704","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40291-026-00836-7","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:53:05Z","timestamp":1774857185000},"page":"475-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance"],"prefix":"10.1007","volume":"30","author":[{"given":"Kl\u00e1ra","family":"Ba\u010furov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Kapustov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kotulov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edt\u011bzslav","family":"Brinsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Piherov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e1clav","family":"Janou\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pohludka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Richt\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Jel\u00ednek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Chyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-0106","authenticated-orcid":false,"given":"Tereza","family":"\u0160ev\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"836_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"836_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997. https:\/\/doi.org\/10.1038\/ncomms3997.","journal-title":"Nat Commun"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen IIIHR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957\u20139. https:\/\/doi.org\/10.1182\/blood-2009-07-230722.","journal-title":"Blood"},{"key":"836_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2022","unstructured":"Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol. 2022;41:1383\u201392. https:\/\/doi.org\/10.1200\/JCO.22.01226.","journal-title":"J Clin Oncol"},{"key":"836_CR5","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"J-J Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s J-J, Cedena M-T, Puig N, Burgos L, Perez JJ, Cordon L, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol. 2022;40:3151\u201361. https:\/\/doi.org\/10.1200\/JCO.21.01365.","journal-title":"J Clin Oncol"},{"key":"836_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01286-w","volume":"15","author":"X Lu","year":"2025","unstructured":"Lu X, Andersen EF, Banerjee R, Eno CC, Gonzales PR, Kumar S, et al. Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group. Blood Cancer J. 2025;15:86.","journal-title":"Blood Cancer J"},{"key":"836_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"836_CR8","first-page":"2049","volume":"109","author":"R Szalat","year":"2024","unstructured":"Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024;109:2049\u201359.","journal-title":"Haematologica"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"836_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2019","unstructured":"Paiva B, Puig N, Cedena M-T, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales M-B, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2019;38:784\u201392. https:\/\/doi.org\/10.1200\/JCO.19.01231.","journal-title":"J Clin Oncol"},{"key":"836_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139:835\u201344.","journal-title":"Blood"},{"key":"836_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00891-8","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Li J, Zhang R, Li J, Chen L, Jin Y. Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma. Discov Oncol. 2024;15:38. https:\/\/doi.org\/10.1007\/s12672-024-00891-8.","journal-title":"Discov Oncol"},{"key":"836_CR13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1182\/blood.2023020284","volume":"142","author":"M Mohty","year":"2023","unstructured":"Mohty M, Avet-Loiseau H, Malard F, Harousseau J-L. Potential future direction of measurable residual disease evaluation in multiple myeloma. Blood. 2023;142:1509\u201317. https:\/\/doi.org\/10.1182\/blood.2023020284.","journal-title":"Blood"},{"key":"836_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/ejh.14316","volume":"114","author":"L Muronova","year":"2025","unstructured":"Muronova L, Soucek O, Zihala D, Sevcikova T, Popkova T, Plonkova H, et al. Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry. Eur J Haematol. 2025;114:155\u201363. https:\/\/doi.org\/10.1111\/ejh.14316.","journal-title":"Eur J Haematol"},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","volume":"6","author":"O Landgren","year":"2025","unstructured":"Landgren O, Devlin SM. Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap. Blood Cancer Discov. 2025;6:13\u201322.","journal-title":"Blood Cancer Discov"},{"key":"836_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1182\/blood.2024027674","volume":"146","author":"S Giri","year":"2025","unstructured":"Giri S, Dhakal B, Callander NS, Medvedova E, Godby K, Dholaria BR, et al. Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma. Blood. 2025;146:707\u201316. https:\/\/doi.org\/10.1182\/blood.2024027674.","journal-title":"Blood"},{"key":"836_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","volume":"15","author":"A Medina-Herrera","year":"2023","unstructured":"Medina-Herrera A, Sarasquete ME, Jim\u00e9nez C, Puig N, Garc\u00eda-Sanz R. Minimal residual disease in multiple myeloma: past, present, and future. Cancers (Basel). 2023;15:3687.","journal-title":"Cancers (Basel)"},{"key":"836_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","volume":"12","author":"S Mailankody","year":"2015","unstructured":"Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12:286\u201395.","journal-title":"Nat Rev Clin Oncol"},{"key":"836_CR19","unstructured":"Ahmed A, Killeen RB. Relapsed and refractory multiple myeloma. [Updated 2023 Jun 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK592405\/."},{"key":"836_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016;30:1005\u201317.","journal-title":"Leukemia"},{"key":"836_CR21","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u201318.","journal-title":"Lancet Oncol"},{"key":"836_CR22","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","volume":"34","author":"NJ Bahlis","year":"2020","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34:1875\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0711-6.","journal-title":"Leukemia"},{"key":"836_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clml.2023.02.006","volume":"23","author":"M-V Mateos","year":"2023","unstructured":"Mateos M-V, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, et al. Comparative efficacy of teclistamab versus physician\u2019s choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:385\u201393. https:\/\/doi.org\/10.1016\/j.clml.2023.02.006.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"836_CR24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728\u201334. https:\/\/doi.org\/10.1200\/JCO.2017.76.5032.","journal-title":"J Clin Oncol"},{"key":"836_CR25","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138. https:\/\/doi.org\/10.1038\/leu.2013.313.","journal-title":"Leukemia"},{"key":"836_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104560","volume":"205","author":"MZ Jakobsen","year":"2025","unstructured":"Jakobsen MZ, Br\u00f8ndum RF, Gregersen H, Due H, Dybk\u00e6r K. A systematic literature review on clonal evolution events preceding relapse in multiple myeloma. Crit Rev Oncol Hematol. 2025;205:104560.","journal-title":"Crit Rev Oncol Hematol"},{"key":"836_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","volume":"2017","author":"P Sonneveld","year":"2017","unstructured":"Sonneveld P. Management of multiple myeloma in the relapsed\/refractory patient. Hematol Am Soc Hematol Educ Progr. 2017;2017:508\u201317.","journal-title":"Hematol Am Soc Hematol Educ Progr."},{"key":"836_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168.","journal-title":"Blood Rev"},{"key":"836_CR29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. 2019;10:1121.","journal-title":"Front Immunol"},{"key":"836_CR30","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56:1878\u201389. https:\/\/doi.org\/10.1038\/s41588-024-01853-0.","journal-title":"Nat Genet"},{"key":"836_CR31","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","volume":"20","author":"PL Bergsagel","year":"2001","unstructured":"Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611\u201322. https:\/\/doi.org\/10.1038\/sj.onc.1204641.","journal-title":"Oncogene"},{"key":"836_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","volume":"1","author":"EH Rustad","year":"2020","unstructured":"Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020;1:258\u201373.","journal-title":"Blood Cancer Discov"},{"key":"836_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2021.04.014","volume":"123","author":"F Maura","year":"2022","unstructured":"Maura F, Boyle EM, Rustad EH, Ashby C, Kaminetzky D, Bruno B, et al. Chromothripsis as a pathogenic driver of multiple myeloma. Semin Cell Dev Biol. 2022;123:115\u201323.","journal-title":"Semin Cell Dev Biol"},{"key":"836_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019;10:3835. https:\/\/doi.org\/10.1038\/s41467-019-11680-1.","journal-title":"Nat Commun"},{"key":"836_CR35","doi-asserted-by":"publisher","first-page":"27854","DOI":"10.18632\/oncotarget.15718","volume":"8","author":"CK Stein","year":"2017","unstructured":"Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, et al. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget. 2017;8:27854\u201367.","journal-title":"Oncotarget"},{"key":"836_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061360","volume":"10","author":"J Burroughs Garc\u00eca","year":"2021","unstructured":"Burroughs Garc\u00eca J, Eufemiese RA, Storti P, Sammarelli G, Craviotto L, Todaro G, et al. Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets. Cells. 2021;10:1360.","journal-title":"Cells"},{"key":"836_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/2643-3249.BCD-20-0081","volume":"1","author":"BA Walker","year":"2020","unstructured":"Walker BA. The chromosome 13 conundrum in multiple myeloma. Blood Cancer Discov. 2020;1:16\u20137.","journal-title":"Blood Cancer Discov"},{"key":"836_CR38","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","volume":"17","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17:7776\u201384.","journal-title":"Clin Cancer Res"},{"key":"836_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42:1229\u201340.","journal-title":"J Clin Oncol"},{"key":"836_CR40","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1158\/1078-0432.CCR-21-3695","volume":"28","author":"P Sudha","year":"2022","unstructured":"Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, et al. Myeloma Genome Project Panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma. Clin Cancer Res. 2022;28:2854\u201364.","journal-title":"Clin Cancer Res"},{"key":"836_CR41","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","volume":"7","author":"MK Samur","year":"2023","unstructured":"Samur MK, Aktas Samur A, Corre J, Lannes R, Shah P, Anderson K, et al. Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023;7:6599\u2013603.","journal-title":"Blood Adv"},{"key":"836_CR42","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911\u201320.","journal-title":"J Clin Oncol"},{"key":"836_CR43","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41467-024-45000-z","volume":"15","author":"C Terragna","year":"2024","unstructured":"Terragna C, Poletti A, Solli V, Martello M, Zamagni E, Pantani L, et al. Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in multiple myeloma patients with specific genomic, transcriptional and adverse clinical features. Nat Commun. 2024;15:1551. https:\/\/doi.org\/10.1038\/s41467-024-45000-z.","journal-title":"Nat Commun"},{"key":"836_CR44","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","volume":"12","author":"B Oben","year":"2021","unstructured":"Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, et al. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun. 2021;12:1861.","journal-title":"Nat Commun"},{"key":"836_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, et al. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019;33:457\u201368. https:\/\/doi.org\/10.1038\/s41375-018-0206-x.","journal-title":"Leukemia"},{"key":"836_CR46","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","volume":"57","author":"J-B Alberge","year":"2025","unstructured":"Alberge J-B, Dutta AK, Poletti A, Coorens THH, Lightbody ED, Toenges R, et al. Genomic landscape of multiple myeloma and its precursor conditions. Nat Genet. 2025;57:1493\u2013503. https:\/\/doi.org\/10.1038\/s41588-025-02196-0.","journal-title":"Nat Genet"},{"key":"836_CR47","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/blood-2018-08-872226","volume":"132","author":"EM Boyle","year":"2018","unstructured":"Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, et al. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018;132:2775\u20137. https:\/\/doi.org\/10.1182\/blood-2018-08-872226.","journal-title":"Blood"},{"key":"836_CR48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/ejh.13993","volume":"111","author":"D Fotiou","year":"2023","unstructured":"Fotiou D, Theodorakakou F, Gavriatopoulou M, Migkou M, Malandrakis P, Ntanasis-Stathopoulos I, et al. Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies. Eur J Haematol. 2023;111:271\u20138. https:\/\/doi.org\/10.1111\/ejh.13993.","journal-title":"Eur J Haematol"},{"key":"836_CR49","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","volume":"104","author":"JR Jones","year":"2019","unstructured":"Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019;104:1440\u201350.","journal-title":"Haematologica"},{"key":"836_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022;13:4517. https:\/\/doi.org\/10.1038\/s41467-022-32145-y.","journal-title":"Nat Commun"},{"key":"836_CR51","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","volume":"36","author":"K Misund","year":"2022","unstructured":"Misund K, Hofste op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, et al. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. 2022;36:1887\u201397. https:\/\/doi.org\/10.1038\/s41375-022-01597-y.","journal-title":"Leukemia"},{"key":"836_CR52","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/blood.2020005885","volume":"137","author":"YJ Shen","year":"2021","unstructured":"Shen YJ, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd RA, Moschetta M, et al. Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021;137:2360\u201372. https:\/\/doi.org\/10.1182\/blood.2020005885.","journal-title":"Blood"},{"key":"836_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","volume":"35","author":"K Allmeroth","year":"2021","unstructured":"Allmeroth K, Horn M, Kroef V, Miethe S, M\u00fcller R-U, Denzel MS. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia. 2021;35:887\u201392. https:\/\/doi.org\/10.1038\/s41375-020-0989-4.","journal-title":"Leukemia"},{"key":"836_CR54","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3324\/haematol.2021.279360","volume":"107","author":"N Giesen","year":"2022","unstructured":"Giesen N, Paramasivam N, Toprak UH, Huebschmann D, Xu J, Uhrig S, et al. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica. 2022;107:1891\u2013901.","journal-title":"Haematologica"},{"key":"836_CR55","unstructured":"Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, et al. Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH). Blood. 2026;blood.2025029996."},{"key":"836_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01096-6","volume":"14","author":"B Ziccheddu","year":"2024","unstructured":"Ziccheddu B, Giannotta C, D\u2019Agostino M, Bertuglia G, Saraci E, Oliva S, et al. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma. Blood Cancer J. 2024;14:117. https:\/\/doi.org\/10.1038\/s41408-024-01096-6.","journal-title":"Blood Cancer J"},{"key":"836_CR57","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"836_CR58","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2023022499","volume":"143","author":"H Lee","year":"2024","unstructured":"Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in\u00a0multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024;143:1211\u20137.","journal-title":"Blood"},{"key":"836_CR59","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.2022017094","volume":"141","author":"MK Samur","year":"2023","unstructured":"Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, et al. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023;141:1724\u201336. https:\/\/doi.org\/10.1182\/blood.2022017094.","journal-title":"Blood"},{"key":"836_CR60","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","volume":"27","author":"B Ziccheddu","year":"2021","unstructured":"Ziccheddu B, Da Vi\u00e0 MC, Lionetti M, Maeda A, Morlupi S, Dugo M, et al. Functional impact of genomic complexity on the transcriptome of multiple myeloma. Clin Cancer Res. 2021;27:6479\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4366.","journal-title":"Clin Cancer Res"},{"key":"836_CR61","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100\u20135. https:\/\/doi.org\/10.1182\/blood-2011-11-390658.","journal-title":"Blood"},{"key":"836_CR62","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587\u201397.","journal-title":"Blood"},{"key":"836_CR63","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/sj.leu.2402125","volume":"15","author":"R Fonseca","year":"2001","unstructured":"Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15:981\u20136. https:\/\/doi.org\/10.1038\/sj.leu.2402125.","journal-title":"Leukemia"},{"key":"836_CR64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","volume":"20","author":"WJ Chng","year":"2007","unstructured":"Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20:571\u201396.","journal-title":"Best Pract Res Clin Haematol"},{"key":"836_CR65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335\u201348. https:\/\/doi.org\/10.1038\/nrc3257.","journal-title":"Nat Rev Cancer"},{"key":"836_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00610-y","volume":"12","author":"M Martello","year":"2022","unstructured":"Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, et al. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. Blood Cancer J. 2022;12:15. https:\/\/doi.org\/10.1038\/s41408-022-00610-y.","journal-title":"Blood Cancer J"},{"key":"836_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar VM, Jaye DL, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun. 2019;10:1911.","journal-title":"Nat Commun"},{"key":"836_CR68","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/leu.2016.370","volume":"31","author":"IJF Hofman","year":"2017","unstructured":"Hofman IJF, van Duin M, De Bruyne E, Fancello L, Mulligan G, Geerdens E, et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia. 2017;31:1706\u201314. https:\/\/doi.org\/10.1038\/leu.2016.370.","journal-title":"Leukemia"},{"key":"836_CR69","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91\u2013101.","journal-title":"Cancer Cell"},{"key":"836_CR70","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024;11:e693-707.","journal-title":"Lancet Haematol"},{"key":"836_CR71","doi-asserted-by":"publisher","first-page":"34784","DOI":"10.18632\/oncotarget.26196","volume":"9","author":"M Ishibashi","year":"2018","unstructured":"Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, et al. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget. 2018;9:34784\u201393.","journal-title":"Oncotarget"},{"key":"836_CR72","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604\u201316. https:\/\/doi.org\/10.1038\/s41375-018-0037-9.","journal-title":"Leukemia"},{"key":"836_CR73","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kort\u00fcm","year":"2016","unstructured":"Kort\u00fcm KM, Mai EK, Hanafiah NH, Shi C-X, Zhu Y-X, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128:1226\u201333.","journal-title":"Blood"},{"key":"836_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.1","volume":"6","author":"KM Kortuem","year":"2016","unstructured":"Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, et al. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016;6:e397. https:\/\/doi.org\/10.1038\/bcj.2016.1.","journal-title":"Blood Cancer J"},{"key":"836_CR75","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng W-J, et al. Promiscuous mutations activate the noncanonical NF-\u03baB pathway in multiple myeloma. Cancer Cell. 2007;12:131\u201344.","journal-title":"Cancer Cell"},{"key":"836_CR76","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"836_CR77","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"836_CR78","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"836_CR79","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"836_CR80","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360\u201376.","journal-title":"Mayo Clin Proc"},{"key":"836_CR81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893","volume":"0","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;0:JCO-24-01893. https:\/\/doi.org\/10.1200\/JCO-24-01893.","journal-title":"J Clin Oncol"},{"issue":"11","key":"836_CR82","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1038\/s41375-025-02654-y","volume":"39","author":"S Zanwar","year":"2025","unstructured":"Zanwar S, Rajkumar SV. Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders. Leukemia. 2025;39(11):2610\u20137. https:\/\/doi.org\/10.1038\/s41375-025-02654-y.","journal-title":"Leukemia"},{"key":"836_CR83","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1200\/JCO-24-01253","volume":"43","author":"MF Kaiser","year":"2025","unstructured":"Kaiser MF, Sonneveld P, Cairns DA, Raab MS, San-Miguel Izquierdo J, Zhang R, et al. Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2679\u201391. https:\/\/doi.org\/10.1200\/JCO-24-01253.","journal-title":"J Clin Oncol"},{"key":"836_CR84","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433520","volume":"44","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, D\u2019Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies. Am Soc Clin Oncol Educ B. 2024;44:e433520. https:\/\/doi.org\/10.1200\/EDBK_433520.","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"836_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00576-3","volume":"12","author":"CY Soekojo","year":"2022","unstructured":"Soekojo CY, Chung T-H, Furqan MS, Chng WJ. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022;12:24. https:\/\/doi.org\/10.1038\/s41408-021-00576-3.","journal-title":"Blood Cancer J"},{"key":"836_CR86","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4065\/82.3.323","volume":"82","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Rajkumar SV, Gertz MA, Lacy MQ, Kyle RA, Greipp PR, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323\u201341. https:\/\/doi.org\/10.4065\/82.3.323.","journal-title":"Mayo Clin Proc"},{"key":"836_CR87","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","volume":"84","author":"SK Kumar","year":"2009","unstructured":"Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84:1095\u2013110.","journal-title":"Mayo Clin Proc"},{"key":"836_CR88","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","volume":"92","author":"D Dingli","year":"2017","unstructured":"Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017;92:578\u201398.","journal-title":"Mayo Clin Proc"},{"key":"836_CR89","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ajcp\/aqad108","volume":"161","author":"M-F Gagnon","year":"2024","unstructured":"Gagnon M-F, Midthun SM, Fangel JA, Schuh CM, Luoma IM, Pearce KE, et al. Superior detection rate of plasma cell FISH using FACS-FISH. Am J Clin Pathol. 2024;161:60\u201370. https:\/\/doi.org\/10.1093\/ajcp\/aqad108.","journal-title":"Am J Clin Pathol"},{"key":"836_CR90","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/jalm\/jfaf044","volume":"10","author":"JJ L\u00f3pez Rivera","year":"2025","unstructured":"L\u00f3pez Rivera JJ, Gomez-Lopera N, Moreno-Garcia DJ, Orduz-Rodriguez R, Combariza-Vallejo JF, Isaza-Ruget M. Plasma cell enrichment and new genomic approaches in multiple myeloma: a scoping review. J Appl Lab Med. 2025;10:1292\u2013310. https:\/\/doi.org\/10.1093\/jalm\/jfaf044.","journal-title":"J Appl Lab Med"},{"key":"836_CR91","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Guti\u00e9rrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272\u20137.","journal-title":"Haematologica"},{"key":"836_CR92","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/s41375-024-02237-3","volume":"38","author":"J Cui","year":"2024","unstructured":"Cui J, Liu Y, Lv R, Yan W, Xu J, Li L, et al. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain\/amp(1q) in multiple myeloma. Leukemia. 2024;38:1299\u2013306. https:\/\/doi.org\/10.1038\/s41375-024-02237-3.","journal-title":"Leukemia"},{"key":"836_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;9:1691. https:\/\/doi.org\/10.1038\/s41467-018-04001-5.","journal-title":"Nat Commun"},{"issue":"11","key":"836_CR94","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","volume":"32","author":"PH Hoang","year":"2018","unstructured":"Hoang PH, Dobbins SE, Cornish AJ, Chubb D, Law PJ, Kaiser M, et al. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia. 2018;32(11):2459\u201370.","journal-title":"Leukemia"},{"key":"836_CR95","first-page":"36","volume":"27","author":"X-F Huang","year":"2020","unstructured":"Huang X-F, Jian S, Lu J-L, Shen K-N, Feng J, Zhang C-L, et al. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. Amyloid Int J Exp Clin Investig. 2020;27:36\u201344.","journal-title":"Amyloid Int J Exp Clin Investig."},{"key":"836_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30694-w","volume":"13","author":"M Bustoros","year":"2022","unstructured":"Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, et al. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022;13:3449.","journal-title":"Nat Commun"},{"key":"836_CR97","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood.2022017010","volume":"141","author":"N Ansari-Pour","year":"2023","unstructured":"Ansari-Pour N, Samur M, Flynt E, Gooding S, Towfic F, Stong N, et al. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma. Blood. 2023;141:620\u201333.","journal-title":"Blood"},{"key":"836_CR98","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-4939-7865-6_6","volume-title":"Multiple myeloma: methods and protocols","author":"BA Walker","year":"2018","unstructured":"Walker BA. Whole exome sequencing in multiple myeloma to identify somatic single nucleotide variants and key translocations involving immunoglobulin loci and MYC BT. In: Euck C, Weinhold N, editors. Multiple myeloma: methods and protocols. New York: Springer, New York; 2018. p. 71\u201395. https:\/\/doi.org\/10.1007\/978-1-4939-7865-6_6."},{"key":"836_CR99","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, Schroeder MC, O\u2019Laughlin M, Wilson R, MacMillan S, Bohannon A, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021;384:924\u201335.","journal-title":"N Engl J Med"},{"key":"836_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.72","volume":"6","author":"N Bolli","year":"2016","unstructured":"Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016;6:e467. https:\/\/doi.org\/10.1038\/bcj.2016.72.","journal-title":"Blood Cancer J"},{"key":"836_CR101","unstructured":"Mayo Foundation for Medical Education and Research. Targeted genes interrogated by MayoComplete plasma cell myeloma next-generation sequencing. 2025. Available from: https:\/\/www.mayocliniclabs.com\/-\/media\/it-mmfiles\/Special-Instructions\/3\/2\/0\/Targeted-Genes-Plasma-Cell-Myeloma-Next-Gen-Sequencing. Accessed 14 Feb 2026."},{"key":"836_CR102","unstructured":"Univ8 Genomics. EuroClonality-NDC. 2025. Available from: https:\/\/univ8genomics.com\/euroclonality-ndc\/. Accessed 14 Feb 2026."},{"key":"836_CR103","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jmoldx.2021.05.007","volume":"23","author":"V Navrkalova","year":"2021","unstructured":"Navrkalova V, Plevova K, Hynst J, Pal K, Mareckova A, Reigl T, et al. LYmphoid neXt-generation sequencing (LYNX) panel: a comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies. J Mol Diagn. 2021;23:959\u201374. https:\/\/doi.org\/10.1016\/j.jmoldx.2021.05.007.","journal-title":"J Mol Diagn"},{"key":"836_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0264-y","volume":"9","author":"V Yellapantula","year":"2019","unstructured":"Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 2019;9:101. https:\/\/doi.org\/10.1038\/s41408-019-0264-y.","journal-title":"Blood Cancer J"},{"issue":"11","key":"836_CR105","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.3324\/haematol.2018.188839","volume":"103","author":"Y Ruiz-Heredia","year":"2018","unstructured":"Ruiz-Heredia Y, S\u00e1nchez-Vega B, Onecha E, Barrio S, Alonso R, Mart\u00ednez-\u00c1vila JC, et al. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica. 2018;103(11):e544\u20138.","journal-title":"Haematologica"},{"issue":"20","key":"836_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205169","volume":"14","author":"JM Rosa-Rosa","year":"2022","unstructured":"Rosa-Rosa JM, Cuenca I, Medina A, V\u00e1zquez I, S\u00e1nchez-delaCruz A, Buenache N, et al. NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial. Cancers (Basel). 2022;14(20):5169.","journal-title":"Cancers (Basel)"},{"key":"836_CR107","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","volume":"127","author":"J He","year":"2016","unstructured":"He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, et al. Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016;127:3004\u201314.","journal-title":"Blood"},{"key":"836_CR108","first-page":"2436","volume":"110","author":"A Poletti","year":"2025","unstructured":"Poletti A, Taurisano B, Mazzocchetti G, Lionetti M, Martello M, Vuong VM, et al. Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma. Haematologica. 2025;110:2436\u201350.","journal-title":"Haematologica"},{"key":"836_CR109","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1182\/blood.2022015853","volume":"140","author":"EJ Duncavage","year":"2022","unstructured":"Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, et al. Genomic profiling for clinical decision making in\u00a0myeloid neoplasms and acute leukemia. Blood. 2022;140:2228\u201347. https:\/\/doi.org\/10.1182\/blood.2022015853.","journal-title":"Blood"},{"key":"836_CR110","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41576-020-0236-x","volume":"21","author":"GA Logsdon","year":"2020","unstructured":"Logsdon GA, Vollger MR, Eichler EE. Long-read human genome sequencing and its applications. Nat Rev Genet. 2020;21:597\u2013614.","journal-title":"Nat Rev Genet"},{"key":"836_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-024-10440-w","volume":"25","author":"W Liu-Wei","year":"2024","unstructured":"Liu-Wei W, van der Toorn W, Bohn P, H\u00f6lzer M, Smyth RP, von Kleist M. Sequencing accuracy and systematic errors of nanopore direct RNA sequencing. BMC Genomics. 2024;25:528. https:\/\/doi.org\/10.1186\/s12864-024-10440-w.","journal-title":"BMC Genomics"},{"key":"836_CR112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207422","volume":"144","author":"S Han","year":"2024","unstructured":"Han S, Afrin N, Tolhuis B, Truger M, Raab P, Munawar U, et al. Implementing Hifi sequencing for enhanced genomic and methylome characterization in multiple myeloma. Blood. 2024;144:7490. https:\/\/doi.org\/10.1182\/blood-2024-207422.","journal-title":"Blood"},{"key":"836_CR113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200043","volume":"144","author":"A Mikulasova","year":"2024","unstructured":"Mikulasova A, Liu E, Becker N, Sudha P, Abonour R, Walker BA. Multiomics data integration in the complete myeloma genome reveals frequent centromeric rearrangements and their epigenomic consequences. Blood. 2024;144:768. https:\/\/doi.org\/10.1182\/blood-2024-200043.","journal-title":"Blood"},{"key":"836_CR114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6121","volume":"146","author":"B Ariceta","year":"2025","unstructured":"Ariceta B, Aguirre-Ruiz P, Castro A, San Martin-Uriz P, Vicente S, Larrayoz MJ, et al. Targeted long-read sequencing with adaptive sampling in multiple myeloma: a pilot study toward a unified diagnostic platform. Blood. 2025;146:6121.","journal-title":"Blood"},{"key":"836_CR115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7452","volume":"146","author":"M Papatsirou","year":"2025","unstructured":"Papatsirou M, Kontos C, Ntanasis-Stathopoulos I, Tsiakanikas P, Liacos C-I, Gavriatopoulou M, et al. Nanopore sequencing-based profiling of circular RNAs in multiple myeloma uncovers circNFATC3 as a promising prognostic biomarker. Blood. 2025;146:7452. https:\/\/doi.org\/10.1182\/blood-2025-7452.","journal-title":"Blood"},{"key":"836_CR116","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nmeth.4184","volume":"14","author":"JT Simpson","year":"2017","unstructured":"Simpson JT, Workman RE, Zuzarte PC, David M, Dursi LJ, Timp W. Detecting DNA cytosine methylation using nanopore sequencing. Nat Methods. 2017;14:407\u201310. https:\/\/doi.org\/10.1038\/nmeth.4184.","journal-title":"Nat Methods"},{"key":"836_CR117","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1093\/bioinformatics\/btz276","volume":"35","author":"P Ni","year":"2019","unstructured":"Ni P, Huang N, Zhang Z, Wang D-P, Liang F, Miao Y, et al. DeepSignal: detecting DNA methylation state from Nanopore sequencing reads using deep-learning. Bioinformatics. 2019;35:4586\u201395. https:\/\/doi.org\/10.1093\/bioinformatics\/btz276.","journal-title":"Bioinformatics"},{"key":"836_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23778-6","volume":"12","author":"ZW-S Yuen","year":"2021","unstructured":"Yuen ZW-S, Srivastava A, Daniel R, McNevin D, Jack C, Eyras E. Systematic benchmarking of tools for CpG methylation detection from nanopore sequencing. Nat Commun. 2021;12:3438. https:\/\/doi.org\/10.1038\/s41467-021-23778-6.","journal-title":"Nat Commun"},{"key":"836_CR119","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ajhg.2021.06.001","volume":"108","author":"K Neveling","year":"2021","unstructured":"Neveling K, Mantere T, Vermeulen S, Oorsprong M, van Beek R, Kater-Baats E, et al. Next-generation cytogenetics: comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping. Am J Hum Genet. 2021;108:1423\u201335. https:\/\/doi.org\/10.1016\/j.ajhg.2021.06.001.","journal-title":"Am J Hum Genet"},{"key":"836_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194687","volume":"15","author":"A Gigu\u00e8re","year":"2023","unstructured":"Gigu\u00e8re A, Raymond-Bouchard I, Collin V, Claveau J-S, H\u00e9bert J, LeBlanc R. Optical genome mapping reveals the complex genetic landscape of myeloma. Cancers (Basel). 2023;15:4687.","journal-title":"Cancers (Basel)"},{"key":"836_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93835-z","volume":"11","author":"E Kriegova","year":"2021","unstructured":"Kriegova E, Fillerova R, Minarik J, Savara J, Manakova J, Petrackova A, et al. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep. 2021;11:14671.","journal-title":"Sci Rep"},{"key":"836_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123263","volume":"11","author":"AWC Pang","year":"2023","unstructured":"Pang AWC, Kosco K, Sahajpal NS, Sridhar A, Hauenstein J, Clifford B, et al. Analytic validation of optical genome mapping in hematological malignancies. Biomedicines. 2023;11:3263.","journal-title":"Biomedicines"},{"key":"836_CR123","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ajh.27175","volume":"99","author":"B Levy","year":"2024","unstructured":"Levy B, Kanagal-Shamanna R, Sahajpal NS, Neveling K, Rack K, Dewaele B, et al. A framework for the clinical implementation of optical genome mapping in hematologic malignancies. Am J Hematol. 2024;99:642\u201361. https:\/\/doi.org\/10.1002\/ajh.27175.","journal-title":"Am J Hematol"},{"key":"836_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01059-x","volume":"14","author":"YS Zou","year":"2024","unstructured":"Zou YS, Klausner M, Ghabrial J, Stinnett V, Long P, Morsberger L, et al. A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping. Blood Cancer J. 2024;14:78. https:\/\/doi.org\/10.1038\/s41408-024-01059-x.","journal-title":"Blood Cancer J"},{"key":"836_CR125","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jmoldx.2025.01.003","volume":"27","author":"H Guermouche","year":"2025","unstructured":"Guermouche H, Roynard P, Servoli F, Lestringant V, Quilichini B, Terr\u00e9 C, et al. Deciphering genomic complexity of multiple myeloma using optimized optical genome mapping. J Mol Diagn. 2025;27:306\u201322. https:\/\/doi.org\/10.1016\/j.jmoldx.2025.01.003.","journal-title":"J Mol Diagn"},{"key":"836_CR126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173685","volume":"142","author":"DD Abelman","year":"2023","unstructured":"Abelman DD, Eagles J, Pedersen S, Danesh A, Croucher D, Bruce JP, et al. Cell-free DNA from blood or bone marrow as alternatives to bone marrow cells for molecular diagnostics and monitoring of multiple myeloma. Blood. 2023;142:4693. https:\/\/doi.org\/10.1182\/blood-2023-173685.","journal-title":"Blood"},{"key":"836_CR127","volume":"20","author":"A-MJ Marivel","year":"2023","unstructured":"Marivel A-MJ, Ma Y, Becker TM, Verma A, Trieu S, Roberts TL, et al. The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma. Leuk Res Rep. 2023;20:100393.","journal-title":"Leuk Res Rep"},{"key":"836_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01185-6","volume":"14","author":"M Martello","year":"2024","unstructured":"Martello M, Solli V, Mazzocchetti G, Solimando AG, Bezzi D, Taurisano B, et al. High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis. Blood Cancer J. 2024;14:208. https:\/\/doi.org\/10.1038\/s41408-024-01185-6.","journal-title":"Blood Cancer J"},{"key":"836_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852573","volume":"12","author":"X Ye","year":"2022","unstructured":"Ye X, Li W, Zhang L, Yu J. Clinical significance of circulating cell-free DNA detection in multiple myeloma: a meta-analysis. Front Oncol. 2022;12:852573.","journal-title":"Front Oncol"},{"key":"836_CR130","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","volume":"36","author":"JM Waldschmidt","year":"2022","unstructured":"Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, et al. Cell-free DNA for the detection of emerging treatment failure in relapsed\/refractory multiple myeloma. Leukemia. 2022;36:1078\u201387. https:\/\/doi.org\/10.1038\/s41375-021-01492-y.","journal-title":"Leukemia"},{"key":"836_CR131","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","volume":"32","author":"G Guo","year":"2018","unstructured":"Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, et al. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018;32:1838\u201341. https:\/\/doi.org\/10.1038\/s41375-018-0115-z.","journal-title":"Leukemia"},{"key":"836_CR132","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/ejh.13541","volume":"106","author":"S Deshpande","year":"2021","unstructured":"Deshpande S, Tytarenko RG, Wang Y, Boyle EM, Ashby C, Schinke CD, et al. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. Eur J Haematol. 2021;106:230\u201340. https:\/\/doi.org\/10.1111\/ejh.13541.","journal-title":"Eur J Haematol"},{"key":"836_CR133","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1182\/bloodadvances.2025016480","volume":"9","author":"R Heestermans","year":"2025","unstructured":"Heestermans R, Olsen C, Ameli S, Succari J, Janssen T, De Brouwer W, et al. Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma. Blood Adv. 2025;9:4306\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2025016480.","journal-title":"Blood Adv"},{"key":"836_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00189","volume":"10","author":"N Bolli","year":"2020","unstructured":"Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-generation sequencing for clinical management of multiple myeloma: ready for prime time? Front Oncol. 2020;10:189.","journal-title":"Front Oncol"},{"key":"836_CR135","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/leu.2013.248","volume":"28","author":"DA Landau","year":"2014","unstructured":"Landau DA, Carter SL, Getz G, Wu CJ. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia. 2014;28:34\u201343.","journal-title":"Leukemia"},{"key":"836_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70216","volume":"9","author":"N Bolli","year":"2025","unstructured":"Bolli N, D\u2019Agostino M, Bagratuni T, Boccadoro M, Cavo M, Driessen C, et al. European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma. HemaSphere. 2025;9:e70216. https:\/\/doi.org\/10.1002\/hem3.70216.","journal-title":"HemaSphere"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00836-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00836-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00836-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:07:57Z","timestamp":1778656077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00836-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00836-7","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Technology Agency of the Czech Republic TQ03000338, the European Union project LERCO (No. CZ.10.03.01\/00\/22_003\/0000003), the Czech Health Research Council (NU23\u201003\u201000374), and the SALVAGE project (CZ.02.01.01\/00\/22_008\/0004644) supported by OP JAK, co-financed by the European Union and the State Budget of the Czech Republic. V\u00e1clav Janou\u0161ek was supported by The National Center\u00a0for Medical Genomics (LM2023067).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Roman H\u00e1jek has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda; is a member of advisory boards such as BMS, Takeda, Amgen, Oncopeptides, Sanofi, Janssen, and GSK; and has received support for attending meetings and\/or travel from Amgen, Celgene, Takeda, and Janssen. V\u00e1clav Janou\u0161ek is a co-founder and shareholder of Biodviser Ltd. Kl\u00e1ra Ba\u010furov\u00e1, Veronika Kapustov\u00e1, Jana Kotulov\u00e1, V\u00edt\u011bzslav Brinsa, Lenka Piherov\u00e1, Michal Pohludka, Michal Richt\u00e1\u0159, Tom\u00e1\u0161 Jel\u00ednek,\n                      ,\n                      Zuzana Chyra, and Tereza \u0160ev\u010d\u00edkov\u00e1 have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ZCH, T\u0160, JK, VB, MR, KB: conceptualization, visualization, writing (original draft), writing (review and editing). LP, VJ: writing (review and editing). TJ, RH, MP: writing (review and editing), funding acquisition. VK, KB, ZCH, T\u0160: major contributors to the writing of the manuscript. All the authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}